Anaptysbio (ANAB) Equity Average (2017 - 2025)
Anaptysbio's Equity Average history spans 9 years, with the latest figure at $3.9 million for Q4 2025.
- For Q4 2025, Equity Average fell 94.98% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, down 94.98%, while the annual FY2025 figure was $54.0 million, 32.01% down from the prior year.
- Equity Average reached $3.9 million in Q4 2025 per ANAB's latest filing, up from -$37.1 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $389.3 million in Q1 2021 to a low of -$37.1 million in Q3 2025.
- Average Equity Average over 5 years is $181.0 million, with a median of $152.1 million recorded in 2023.
- Peak YoY movement for Equity Average: increased 3.73% in 2021, then tumbled 178.68% in 2025.
- A 5-year view of Equity Average shows it stood at $370.0 million in 2021, then decreased by 27.07% to $269.9 million in 2022, then tumbled by 61.37% to $104.2 million in 2023, then decreased by 25.54% to $77.6 million in 2024, then crashed by 94.98% to $3.9 million in 2025.
- Per Business Quant, the three most recent readings for ANAB's Equity Average are $3.9 million (Q4 2025), -$37.1 million (Q3 2025), and -$5.4 million (Q2 2025).